苏州盛迪亚生物医药有限公司

Hengrui Pharma Receives Clinical Trial Approvals for Five Oncology Drugs Including Novel KRAS G12D Inhibitor

- Hengrui Pharma and its subsidiaries received NMPA clinical trial approvals for five oncology drugs, including HRS-6093, a novel oral KRAS G12D inhibitor with no similar approved products globally. - The approved pipeline includes SHR-9839, a dual-pathway blocking humanized antibody, and SHR-1826, a c-Met targeting antibody-drug conjugate with cumulative R&D investments totaling over RMB 400 million. - The company's adalimumab injection, already approved for small cell lung cancer treatment in 2023, received additional clinical trial approval alongside SHR-8068, an anti-CTLA-4 monoclonal antibody. - Total cumulative R&D investment across all five programs amounts to approximately RMB 789.27 million, reflecting significant commitment to oncology drug development.